RNA Clinical Trials Articles

1. Overcoming CMC Challenges In The Development Of Conjugated LNP Platforms For In Vivo CAR-T Therapy 11/4/2025

   Overcoming CMC hurdles is key to advancing conjugated LNP platforms for in vivo CAR-T therapy, enabling scalable, precise mRNA delivery to T cells while maintaining stability, potency, and regulatory compliance.

2. Beyond the Hype: Industry Experts on the Reality of mRNA in Cancer Care 10/31/2025

   When I asked a panel of experts at RNA Leaders why mRNA was best positioned to shine in oncology, I was met with a few expected talking points and — better yet — a few I wasn’t expecting. 

3. Tackling Challenges In RNA Stability And Organ Targeting 10/28/2025

   RNA therapeutics are reshaping medicine, but instability and limited organ targeting still pose challenges. Discover how next-gen lipid nanoparticles and smart delivery systems are advancing RNA precision.

4. Developing Exosome-Based RNA Therapeutics For CNS Regeneration 10/24/2025

   Inside the effort to use exosomes as natural nanocarriers that deliver RNA therapeutics safely across the blood–brain barrier to heal damaged neural tissue.

5. Bridging RNA Innovation: A CEO's Guide To European Expansion 10/15/2025

   For RNA biotechs, Europe isn't just the next market — it's the ultimate test of strategy. Here's what CEOs need to know.

6. From Misinformation To Medicine: Forging Bipartisan Support to Reverse Anti-mRNA Policy 10/9/2025

   In this article, I’ll share some of the progress AMM has made and the barriers the organization/our industry is still facing in our efforts to reverse the policy decisions that have been made against mRNA today. Throughout the panel, the speakers also shared their thoughts on the types of messaging we should be considering and/or have started to see making an impact. 

7. Reclaiming mRNA's Story: How U.S. Policy Upheavals Are Pushing Us To Adapt 10/2/2025

   I’d like to believe everyone reading Advancing RNA already knows that mRNA is the greatest. So, this article isn’t going to outline why the U.S. government’s current efforts to disparage mRNA are harmful. Rather, I’d like to focus on how these policies are impacting our industry in both positive and negative ways — starting with a few takeaways I gleaned from a discussion at RNA Leaders. 

8. Translating An Early-Stage mRNA Therapeutic Into The Clinic 8/26/2025

   In the following Q&A, Ethris CMO Thomas Langenickel shares some of his biggest questions and observations about the evolving mRNA therapeutics space that are the most impactful in translating early-stage RNA candidates into the clinic — particularly when that drug product boasts a novel formulation.

9. 5 Takeaways From The MHRA mRNA Guidance 7/28/2025

   Having read and reread the MHRA's guidance on personalized mRNA cancer immunotherapies, the following five takeaways will function somewhat as a mind-meld, combining a few of my own thoughts/takeaways with those of the MHRA.

10. Ancient Molecule, Modern Medicine: The Science, Strategy, & Stakeholders Behind tRNA Therapeutics 7/22/2025

    As we all know well, “unearthing” our molecules’ potential poses numerous technical and business-related challenges for young biotech companies. Here, Werner and I continue our conversation, unpacking some of these internal and external challenges the company is navigating as it strives to bring tRNA to the commercial market.